GH Research ( (GHRS) ) has issued an update.
On February 3, 2025, GH Research PLC announced the launch of a public offering in the U.S. to raise $150 million through the sale of ordinary shares. The offering is subject to market conditions, and the company may grant underwriters an option to purchase an additional $22.5 million in shares. The initiative is strategically aimed at bolstering the company’s financial resources as it advances its pioneering treatments for depression, thereby potentially enhancing its market position and value proposition to stakeholders.
More about GH Research
GH Research PLC is a clinical-stage biopharmaceutical company focused on developing transformative treatments for patients with depression, specifically targeting treatment-resistant depression (TRD) through its innovative mebufotenin therapies.
YTD Price Performance: 34.01%
Average Trading Volume: 78,959
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $551.5M
For detailed information about GHRS stock, go to TipRanks’ Stock Analysis page.